Circulating Th1 and Th17 Cells in Severe Hemophilia A: Associations with Factor VIII Inhibitor Status and Titers
Abstract Purpose Factor VIII (FVIII) inhibitor development is a major complication of replacement therapy in severe hemophilia A (HA). This study investigated circulating T-helper 1 (Th1) and T-helper 17 (Th17) cell frequencies according to inhibitor status and their associations with inhibitor titers. Methods This case-control study included 32 male patients with severe HA (8 inhibitor-positive and 24 inhibitor-negative) and 24 healthy controls. Flow cytometry was used to assess CD4⁺IFN-γ⁺ Th1 and CD4⁺IL-17⁺ Th17 cells and intracellular cytokine mean fluorescence intensity (MFI). Results Overall, Th1 and Th17 cell frequencies and the cytokine MFIs did not differ significantly between HA patients and healthy controls (P > 0.05). Patients with FVIII inhibitors exhibited a significantly lower proportion of Th1 lymphocytes than those without inhibitors (median [IQR]: 2.77% [1.37–2.81] vs. 5.83% [3.47–6.30], *P = 0.003) and healthy controls (2.77% [1.37–2.81] vs. 4.19% [2.88–5.57], *P = 0.014). No significant differences in Th1-cell frequency were observed between inhibitor-negative patients and healthy controls (P > 0.05). Th17-cell percentage and IL-17 MFI did not differ significantly among all groups (P > 0.05). Among inhibitor-positive patients, Th1-cell frequency correlated positively with Th17-cell frequency (r = 0.494, *P = 0.032) and IFN-γ MFI (r = 0.542, *P = 0.016). The proportion of Th1 lymphocytes had a strong inverse correlation with FVIII inhibitor titer (r=-0.708, *P < 0.001). Neither Th1 nor Th17 cell frequency was significantly associated with white blood cell and platelet count, or hemoglobin level. Conclusion Reduced Th1-cell frequency was associated with FVIII inhibitor positivity and higher inhibitor titers. Further studies are needed to validate these results and clarify their clinical significance.
Authors
- Amin Shahsavani (ORCID: https://orcid.org/0000-0002-4592-312X)
- Mehdi Kalani (ORCID: https://orcid.org/0000-0002-7091-6466)
- Hossein Golmoghaddam
- Nargess Arandi (ORCID: https://orcid.org/0000-0001-6489-0979)
- Omid Reza Zekavat (ORCID: https://orcid.org/0000-0002-0008-3198)
- Tahereh Zarei (ORCID: https://orcid.org/0000-0002-2689-0254)
Institutions
- Shiraz University of Medical Sciences (IR)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11509238/v1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- preprint
Funders
- Shiraz University of Medical Sciences
- Shiraz University